IE914477A1 - Antidepression pharmaceutical - Google Patents
Antidepression pharmaceuticalInfo
- Publication number
- IE914477A1 IE914477A1 IE447791A IE447791A IE914477A1 IE 914477 A1 IE914477 A1 IE 914477A1 IE 447791 A IE447791 A IE 447791A IE 447791 A IE447791 A IE 447791A IE 914477 A1 IE914477 A1 IE 914477A1
- Authority
- IE
- Ireland
- Prior art keywords
- weeks
- nicotinamide
- dinucleotide
- adenine
- weekly
- Prior art date
Links
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 claims abstract description 25
- BAWFJGJZGIEFAR-NNYOXOHSSA-N NAD zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-N 0.000 claims abstract description 13
- 229950006238 nadide Drugs 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 208000020401 Depressive disease Diseases 0.000 claims abstract description 7
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 claims abstract 5
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 claims description 9
- 230000003442 weekly effect Effects 0.000 description 17
- 239000002858 neurotransmitter agent Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 8
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 6
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 5
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003001 depressive effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 206010024870 Loss of libido Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010042458 Suicidal ideation Diseases 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000003943 catecholamines Chemical group 0.000 description 1
- 238000009535 clinical urine test Methods 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003955 neuronal function Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4100361A DE4100361C1 (enExample) | 1991-01-04 | 1991-01-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IE914477A1 true IE914477A1 (en) | 1992-07-15 |
Family
ID=6422686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE447791A IE914477A1 (en) | 1991-01-04 | 1991-12-20 | Antidepression pharmaceutical |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP0493861B1 (enExample) |
| JP (1) | JP2519148B2 (enExample) |
| AT (1) | ATE148991T1 (enExample) |
| AU (1) | AU631755B2 (enExample) |
| BR (1) | BR9105183A (enExample) |
| CA (1) | CA2057456C (enExample) |
| DE (2) | DE4100361C1 (enExample) |
| DK (1) | DK0493861T3 (enExample) |
| ES (1) | ES2097181T3 (enExample) |
| GR (1) | GR3022724T3 (enExample) |
| HU (1) | HU213112B (enExample) |
| IE (1) | IE914477A1 (enExample) |
| NO (1) | NO179602C (enExample) |
| PT (1) | PT99962B (enExample) |
| ZA (1) | ZA9244B (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2167104A1 (en) * | 1995-01-17 | 1996-07-18 | Joerg G.D. Birkmayer | Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration |
| US5712259A (en) * | 1996-04-22 | 1998-01-27 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating chronic fatigue syndrome |
| US5668114A (en) * | 1996-05-08 | 1997-09-16 | Birkmayer Pharmaceuticals | NADH and NADPH pharmaceuticals for treating hypertension |
| ES2953842B2 (es) * | 2023-07-17 | 2025-02-14 | Nuadi Europe S L | Tapacubos antipolvo |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3341412A (en) * | 1966-03-04 | 1967-09-12 | Enzomedic Lab Inc | Methods of treating schizophrenia |
| JP2736103B2 (ja) * | 1988-03-01 | 1998-04-02 | ヴァルター・ビルクマイヤー | パーキンソン症候群の治療用医薬、およびその製造方法 |
-
1991
- 1991-01-04 DE DE4100361A patent/DE4100361C1/de not_active Expired - Lifetime
- 1991-11-07 DK DK91250304.2T patent/DK0493861T3/da active
- 1991-11-07 DE DE59108553T patent/DE59108553D1/de not_active Expired - Fee Related
- 1991-11-07 EP EP91250304A patent/EP0493861B1/de not_active Expired - Lifetime
- 1991-11-07 ES ES91250304T patent/ES2097181T3/es not_active Expired - Lifetime
- 1991-11-07 AT AT91250304T patent/ATE148991T1/de not_active IP Right Cessation
- 1991-11-28 BR BR919105183A patent/BR9105183A/pt not_active Application Discontinuation
- 1991-12-10 CA CA002057456A patent/CA2057456C/en not_active Expired - Fee Related
- 1991-12-20 IE IE447791A patent/IE914477A1/en not_active IP Right Cessation
- 1991-12-27 JP JP3346474A patent/JP2519148B2/ja not_active Expired - Fee Related
- 1991-12-31 AU AU90109/91A patent/AU631755B2/en not_active Ceased
-
1992
- 1992-01-02 PT PT99962A patent/PT99962B/pt not_active IP Right Cessation
- 1992-01-03 ZA ZA9244A patent/ZA9244B/xx unknown
- 1992-01-03 NO NO920056A patent/NO179602C/no not_active IP Right Cessation
- 1992-01-03 HU HU9200025A patent/HU213112B/hu not_active IP Right Cessation
-
1997
- 1997-03-03 GR GR970400414T patent/GR3022724T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0493861A2 (de) | 1992-07-08 |
| BR9105183A (pt) | 1992-09-29 |
| DE59108553D1 (de) | 1997-03-27 |
| CA2057456C (en) | 1996-02-06 |
| JP2519148B2 (ja) | 1996-07-31 |
| CA2057456A1 (en) | 1992-07-05 |
| HU9200025D0 (en) | 1992-03-30 |
| EP0493861B1 (de) | 1997-02-19 |
| NO179602C (no) | 1996-11-13 |
| PT99962B (pt) | 1999-06-30 |
| JPH05139978A (ja) | 1993-06-08 |
| AU9010991A (en) | 1992-07-16 |
| ATE148991T1 (de) | 1997-03-15 |
| ES2097181T3 (es) | 1997-04-01 |
| AU631755B2 (en) | 1992-12-03 |
| HUT60141A (en) | 1992-08-28 |
| DK0493861T3 (da) | 1997-08-25 |
| EP0493861A3 (en) | 1993-03-03 |
| ZA9244B (en) | 1992-10-28 |
| NO179602B (no) | 1996-08-05 |
| HU213112B (en) | 1997-02-28 |
| PT99962A (pt) | 1993-02-26 |
| NO920056D0 (no) | 1992-01-03 |
| NO920056L (no) | 1992-07-06 |
| GR3022724T3 (en) | 1997-06-30 |
| DE4100361C1 (enExample) | 1992-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wålinder et al. | Potentiation of the antidepressant action of clomipramine by tryptophan | |
| CZ2000741A3 (cs) | Farmaceutický prostředek | |
| Aprison et al. | Hypersensitive serotonergic receptors: A new hypothesis for one subgroup of unipolar depression derived from an animal model | |
| GROWDON et al. | L‐5‐hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent | |
| Kaur et al. | Differential effects of intrastriatal and intranigral injections of glutamate antagonists on motor behaviour in the reserpine-treated rat | |
| Saletu et al. | Fluvoxamine—a new serotonin re-uptake inhibitor: first clinical and psychometric experiences in depressed patients | |
| EP0462075A2 (en) | Use of uridine in the pharmacological treatment of the peripheral complications of diabetes | |
| CA2297153C (en) | Use of alkanoyl carnitine derivatives for the treatment of attention-deficit/hyperactive disorders | |
| Curry | Concentration‐effect relationships with major and minor tranquilizers | |
| Burke et al. | Phenylethanolamine N‐methyltransferase activity is decreased in Alzheimer's disease brains | |
| Buccafusco et al. | Potential cognitive actions of (n-propargly-(3r)-aminoindan-5-yl)-ethyl, methyl carbamate (tv3326), a novel neuroprotective agent, as assessed in old rhesus monkeys in their performance of versions of a delayed matching task | |
| IE914477A1 (en) | Antidepression pharmaceutical | |
| Kimball | Factors to be, considered in the control and elimination of chronic tissue soreness beneath dentures | |
| Knezevic et al. | Neuroleptic malignant syndrome | |
| Roccaforte et al. | Use of psychostimulants for the elderly | |
| Elwes et al. | Treatment of narcolepsy with L-tyrosine: double-blind placebo-controlled trial | |
| Parnetti et al. | Aniracetam (Ro 13-5057) for the treatment of senile dementia of Alzheimer type: Results of a multicentre clinical study | |
| Dressing et al. | The effects of biperiden on nap sleep after sleep deprivation in depressed patients | |
| Fann et al. | Effect of antidepressant and antimanic drugs on amine uptake in man | |
| Görke et al. | Biochemical and neurophysiological investigations in two forms of Segawa's disease | |
| US4783486A (en) | Tolrestat for hearing impairment | |
| Raskind | Nutrition and cognitive function in the elderly | |
| Giannelli et al. | A combination of hypothalamic phospholipid liposomes with trazodone for treatment of depression: an open controlled study | |
| US8569366B2 (en) | Acetyl L-carnitine for prevention of painful peripheral neuropathy in patients with type 2 diabetes | |
| Kelly | Progress in anxiety states |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Patent lapsed |